In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists



April 23, 2020

Presenter: Pallavi Limaye, Ph.D., DABT, SEKISUI XenoTech Director of Scientific Consulting with special Q&A guest, Brian Ogilvie, Ph.D., SEKISUI XenoTech Vice President of Scientific Consulting

Originally scheduled to be presented at the canceled Society of Toxicology (SOT) 59th Annual Meeting & ToxExpo, our experts are bringing the tradeshow to you! Dr. Limaye will be discussing the intersection of ADME and toxicology in this webinar, followed by a live Q&A to address audience questions and comments.

In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. This ADME 101 webinar will provide insights at a high-level related to regulatory drivers, investigatory objectives, and practical concerns for such studies that are relevant to interested general toxicologists. Participants will gain insight as to the critical need and utility for in vitro ADME and DDI investigations as related to drug development. Regulatory expectations will be reviewed as will points of particular interest for enabling successful achievement of investigatory goals.

Key concepts discussed in this webinar will include:
- Why run these studies?
- Predominant types of in vitro ADME & Drug-Drug Interaction (DDI) studies
- When to conduct these studies
- Areas of concern: Proper design & interpretation
- And other highlights and information...

Download slides:
Questions, comments and requests:
More information on our research services and test systems:
Other previously aired webinars:
Upcoming webinar notifications:
Request a webinar topic:

Cancer ResearchDiagnosticsDrug DiscoveryMass Spectrometry

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.